GSK press releases Follow GSK’s momelotinib granted Orphan Drug Designations in the US and EU for VEXAS syndrome VEXAS syndrome is a rare, life-threatening haemato-inflammatory condition with no approved treatments. https://www.gsk.com/en-gb/media/press-releases/gsk-s-momelotinib-granted-orphan-drug-designations-in-the-us-and-eu-for-vexas-syndrome/ gsk.com
